Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors

NCT01413503 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01413503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01413503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
May 31, 1991
Completion date
May 31, 2009
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paraganglioma, pheochromocytoma